Werth discusses what the 52-week AMETHYST Part A data add to the case for litifilimab in antimalarial-refractory cutaneous lupus erythematosus.
|Slideshows|January 16, 2019
Traditional CV Risk Models May Fall Short in Lupus
While traditional risk factors play a role, factors specific to SLE also contribute to CVD.
Advertisement
Advertisement
Related to this article
Beeline Medicines reported positive topline data meeting primary SRI-4 endpoint at week 48 across all 3 doses in systemic lupus erythematosus.
Population data from Greater Manchester show Black, Asian, and mixed-ethnicity patients with lupus receive greater oral corticosteroid doses.
Advertisement
Advertisement
Trending on Rheumatology Live
1
Retatrutide Cuts Knee OA Pain, With Philip Conaghan, MBBS, PhD
2
Bimekizumab Leads New Wave of PsA Comparative Data: Philip Mease, MD
3
CD19 CAR T Shows Early Remission in Treatment-Refractory RA
4
Adding Tirzepatide Improves PsA Control in Obesity: Philip Mease, MD
5